AI assistant
ARS Pharmaceuticals, Inc. — Director's Dealing 2024
Aug 15, 2024
32159_dirs_2024-08-15_f236d100-428a-4be2-a4a2-5bc215e08565.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-08-13
Reporting Person: Tanimoto Sarina (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-08-13 | Common Stock | S | 14599 | $11.7753 | Disposed | 1481895 | Indirect |
| 2024-08-13 | Common Stock | S | 35401 | $12.7646 | Disposed | 1446494 | Indirect |
| 2024-08-13 | Common Stock | S | 14637 | $11.7734 | Disposed | 1583862 | Indirect |
| 2024-08-13 | Common Stock | S | 35363 | $12.7659 | Disposed | 1548499 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 3407847 | Direct |
| Common Stock | 1547447 | Indirect |
| Common Stock | 4315313 | Indirect |
Footnotes
F1: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.
F2: The weighted average sale price for the transaction report was $11.7753,and the range of prices were between $11.31 and $12.22. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.
F3: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4: The weighted average sale price for the transaction reported was $12.7646, and the range of prices were between $12.24 and $13.085. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5: The weighted average sale price for the transaction reported was $11.7734, and the range of prices were between $11.335 and $12.215. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F6: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.
F7: The weighted average sale price for the transaction reported was $12.7659, and the range of prices were between $12.35 and $13.095. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F8: The Reporting Person is trustee of the trust.